PRLog (Press Release) –
Apr 03, 2008 – RNL Bio, a leading stem cell firm, launched the world’s first stem cell bank for patients infected with Hepatitis B and/or C Virus. Health authorities has restricted virus infected patients from enrolling in general stem cell banks due to the risk of cross contamination of viruses. However, RNL Bio has designed an isolated facility and offers a stem cell bank for virus carries. Liver disease is the fifth highest cause of death in many countries including South Korea and prolonged infection with HBV or HCV could develop cirrhosis and liver cancer. According to a recent report, 23% of HBV carriers developed cirrhosis within 10 years after the onset of a viral infection. The establishment of the stem cell bank will allow hepatitis viral carriers have the benefit of preserving their own stem cells for the preparation of future potential treatments.
About RNL Bio
RNL Bio is in the clinical stages for a stem cell therapeutic for the treatment of peripheral artery disease. Recently, the firm has made a breakthrough in the regeneration of functional liver tissue from fat derived stem cells in collaboration with Dr. Colin McGuckin’s team at Newcastle University. This breakthrough could advance the development of a new stem cell therapy for liver diseases.
About Biostar Stem Cell Bank
RNL Bio has operated ‘Biostar’, a private stem cell bank established with the most state-of-the-
art technology. It is an integrated stem cell bank for storage of stem cells from umbilical cord blood, placenta or fat tissue. In addition to its existing services, the firm will now bank cells from HBV or HCV carriers and offers promotional discounts for new ‘Biostar’ cell bank members who enroll by the end of April.
